Renal Cell Carcinoma | Treatment Sequencing | US | 2019

KEY BENEFITS AND USES

  • Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
  • Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.
  • Identify untapped treatment scenarios and key competitors to aid trial design.
  • Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
  • Discover untapped populations to expand product share and drive strategic decisions.

QUESTIONS ANSWERED

• Where is my product positioned vs. competitors in the treatment journey?

• What are physicians’ most frequent treatment sequences—who is

benefiting and how can I defend my assets share and position?

• What are the market-relevant treatment scenarios according to oncology

experts?

• Where are the untapped business opportunities that I can capitalize

upon?

• How can I optimize trial design and ensure a competitive edge for my

pipeline asset?

GEOGRAPHIES

United States

PRIMARY MARKET RESEARCH

Survey of ~100 U.S. physicians

2019 COVERAGE

Colorectal Cancer (US)

Multiple Myeloma (US)

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia (US)

Non-Small-Cell Lung Cancer (US)

Ovarian Cancer (US)

Prostate Cancer (US)

Renal Cell Carcinoma (US)

KEY FEATURES

  • Market-relevant treatment scenarios and subpopulations from oncology experts
  • Drug share and treatment rates mapped to treatment journey using physician survey data
  • Physicians’ most frequently selected treatment sequences
  • Access to expert oncology analysts for bespoke support

PRODUCT DESCRIPTION

Treatment Sequencing provides disease-specific, sequential treatment

patterns in market-relevant treatment scenarios and drug share mapped to

treatment journey. The quantitative sequencing analysis illuminates drug

positioning through primary market research-based insights from physicians

and DRG oncology experts’ assumptions.